Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study
Summary Background AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis. Methods Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line...
Gespeichert in:
| Veröffentlicht in: | Wiener medizinische Wochenschrift 2020-04, Vol.170 (5-6), p.132-140 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 140 |
|---|---|
| container_issue | 5-6 |
| container_start_page | 132 |
| container_title | Wiener medizinische Wochenschrift |
| container_volume | 170 |
| creator | Peichl, Peter Alten, Rieke Galeazzi, Mauro Lorenz, Hanns-Martin Nüßlein, Hubert Navarro, Federico Elbez, Yedid Chartier, Melanie Hackl, Roland Rauch, Christiane Connolly, Sean E |
| description | Summary
Background
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.
Methods
Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.
Results
Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.
Conclusions
In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients. |
| doi_str_mv | 10.1007/s10354-019-00710-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2309501057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2309501057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-9f045764c3d56027553e86d1e471d493821cbfe023fded5ec5698070fa65045a3</originalsourceid><addsrcrecordid>eNp9kE1vVCEUhompsWPrH-iiYdkNerjA_XA3mVRt0thNTdwRBs7t0NwLU-CmmT_g75Y61aUrcsLzvifnIeSCw0cO0H3KHISSDPjA6siB9W_IiqtWsEb1P0_ICkAKpoTkp-R9zo8AvBtU846cCt4qWckV-bXemmIs7gtNWDAUHwM1wVE7-eCtmWhcio0zZuoDXS-5JG8C3ZviK5zpsy87mna4zKZE76hJZZd88flz7TMTe45pctTVHXRMcaZlh7RhBzSJrjf3N3ffaS6LO5yTt6OZMn54fc_Ijy_X95tv7Pbu681mfcuskF1hwwhSda20wqkWmk4pgX3rOMqOOzmIvuF2OyI0YnToFFrVDj10MJpW1aQRZ-Tq2LtP8WnBXPTss8VpMgHjknUjYFDAQXUVbY6oTTHnhKPeJz-bdNAc9It_ffSvq3_9x7_ua-jytX_Zzuj-Rf4Kr4A4Arl-hQdM-jEuKdSb_1f7GzqIkXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309501057</pqid></control><display><type>article</type><title>Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Peichl, Peter ; Alten, Rieke ; Galeazzi, Mauro ; Lorenz, Hanns-Martin ; Nüßlein, Hubert ; Navarro, Federico ; Elbez, Yedid ; Chartier, Melanie ; Hackl, Roland ; Rauch, Christiane ; Connolly, Sean E</creator><creatorcontrib>Peichl, Peter ; Alten, Rieke ; Galeazzi, Mauro ; Lorenz, Hanns-Martin ; Nüßlein, Hubert ; Navarro, Federico ; Elbez, Yedid ; Chartier, Melanie ; Hackl, Roland ; Rauch, Christiane ; Connolly, Sean E</creatorcontrib><description>Summary
Background
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.
Methods
Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.
Results
Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.
Conclusions
In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.</description><identifier>ISSN: 0043-5341</identifier><identifier>EISSN: 1563-258X</identifier><identifier>DOI: 10.1007/s10354-019-00710-8</identifier><identifier>PMID: 31654156</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Family Medicine ; General Practice ; Geriatrics/Gerontology ; Infectious Diseases ; Internal Medicine ; Medicine ; Medicine & Public Health ; Original Article ; Pharmacology/Toxicology</subject><ispartof>Wiener medizinische Wochenschrift, 2020-04, Vol.170 (5-6), p.132-140</ispartof><rights>Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-9f045764c3d56027553e86d1e471d493821cbfe023fded5ec5698070fa65045a3</citedby><cites>FETCH-LOGICAL-c347t-9f045764c3d56027553e86d1e471d493821cbfe023fded5ec5698070fa65045a3</cites><orcidid>0000-0002-1090-7904</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10354-019-00710-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10354-019-00710-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31654156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peichl, Peter</creatorcontrib><creatorcontrib>Alten, Rieke</creatorcontrib><creatorcontrib>Galeazzi, Mauro</creatorcontrib><creatorcontrib>Lorenz, Hanns-Martin</creatorcontrib><creatorcontrib>Nüßlein, Hubert</creatorcontrib><creatorcontrib>Navarro, Federico</creatorcontrib><creatorcontrib>Elbez, Yedid</creatorcontrib><creatorcontrib>Chartier, Melanie</creatorcontrib><creatorcontrib>Hackl, Roland</creatorcontrib><creatorcontrib>Rauch, Christiane</creatorcontrib><creatorcontrib>Connolly, Sean E</creatorcontrib><title>Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study</title><title>Wiener medizinische Wochenschrift</title><addtitle>Wien Med Wochenschr</addtitle><addtitle>Wien Med Wochenschr</addtitle><description>Summary
Background
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.
Methods
Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.
Results
Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.
Conclusions
In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.</description><subject>Family Medicine</subject><subject>General Practice</subject><subject>Geriatrics/Gerontology</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><issn>0043-5341</issn><issn>1563-258X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1vVCEUhompsWPrH-iiYdkNerjA_XA3mVRt0thNTdwRBs7t0NwLU-CmmT_g75Y61aUrcsLzvifnIeSCw0cO0H3KHISSDPjA6siB9W_IiqtWsEb1P0_ICkAKpoTkp-R9zo8AvBtU846cCt4qWckV-bXemmIs7gtNWDAUHwM1wVE7-eCtmWhcio0zZuoDXS-5JG8C3ZviK5zpsy87mna4zKZE76hJZZd88flz7TMTe45pctTVHXRMcaZlh7RhBzSJrjf3N3ffaS6LO5yTt6OZMn54fc_Ijy_X95tv7Pbu681mfcuskF1hwwhSda20wqkWmk4pgX3rOMqOOzmIvuF2OyI0YnToFFrVDj10MJpW1aQRZ-Tq2LtP8WnBXPTss8VpMgHjknUjYFDAQXUVbY6oTTHnhKPeJz-bdNAc9It_ffSvq3_9x7_ua-jytX_Zzuj-Rf4Kr4A4Arl-hQdM-jEuKdSb_1f7GzqIkXQ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Peichl, Peter</creator><creator>Alten, Rieke</creator><creator>Galeazzi, Mauro</creator><creator>Lorenz, Hanns-Martin</creator><creator>Nüßlein, Hubert</creator><creator>Navarro, Federico</creator><creator>Elbez, Yedid</creator><creator>Chartier, Melanie</creator><creator>Hackl, Roland</creator><creator>Rauch, Christiane</creator><creator>Connolly, Sean E</creator><general>Springer Vienna</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1090-7904</orcidid></search><sort><creationdate>20200401</creationdate><title>Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study</title><author>Peichl, Peter ; Alten, Rieke ; Galeazzi, Mauro ; Lorenz, Hanns-Martin ; Nüßlein, Hubert ; Navarro, Federico ; Elbez, Yedid ; Chartier, Melanie ; Hackl, Roland ; Rauch, Christiane ; Connolly, Sean E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-9f045764c3d56027553e86d1e471d493821cbfe023fded5ec5698070fa65045a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Family Medicine</topic><topic>General Practice</topic><topic>Geriatrics/Gerontology</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peichl, Peter</creatorcontrib><creatorcontrib>Alten, Rieke</creatorcontrib><creatorcontrib>Galeazzi, Mauro</creatorcontrib><creatorcontrib>Lorenz, Hanns-Martin</creatorcontrib><creatorcontrib>Nüßlein, Hubert</creatorcontrib><creatorcontrib>Navarro, Federico</creatorcontrib><creatorcontrib>Elbez, Yedid</creatorcontrib><creatorcontrib>Chartier, Melanie</creatorcontrib><creatorcontrib>Hackl, Roland</creatorcontrib><creatorcontrib>Rauch, Christiane</creatorcontrib><creatorcontrib>Connolly, Sean E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Wiener medizinische Wochenschrift</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peichl, Peter</au><au>Alten, Rieke</au><au>Galeazzi, Mauro</au><au>Lorenz, Hanns-Martin</au><au>Nüßlein, Hubert</au><au>Navarro, Federico</au><au>Elbez, Yedid</au><au>Chartier, Melanie</au><au>Hackl, Roland</au><au>Rauch, Christiane</au><au>Connolly, Sean E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study</atitle><jtitle>Wiener medizinische Wochenschrift</jtitle><stitle>Wien Med Wochenschr</stitle><addtitle>Wien Med Wochenschr</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>170</volume><issue>5-6</issue><spage>132</spage><epage>140</epage><pages>132-140</pages><issn>0043-5341</issn><eissn>1563-258X</eissn><abstract>Summary
Background
AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.
Methods
Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.
Results
Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.
Conclusions
In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>31654156</pmid><doi>10.1007/s10354-019-00710-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1090-7904</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0043-5341 |
| ispartof | Wiener medizinische Wochenschrift, 2020-04, Vol.170 (5-6), p.132-140 |
| issn | 0043-5341 1563-258X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2309501057 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Family Medicine General Practice Geriatrics/Gerontology Infectious Diseases Internal Medicine Medicine Medicine & Public Health Original Article Pharmacology/Toxicology |
| title | Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A11%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abatacept%20retention%20and%20clinical%20outcomes%20in%20Austrian%20patients%20with%20rheumatoid%20arthritis:%20real-world%20data%20from%20the%202-year%20ACTION%20study&rft.jtitle=Wiener%20medizinische%20Wochenschrift&rft.au=Peichl,%20Peter&rft.date=2020-04-01&rft.volume=170&rft.issue=5-6&rft.spage=132&rft.epage=140&rft.pages=132-140&rft.issn=0043-5341&rft.eissn=1563-258X&rft_id=info:doi/10.1007/s10354-019-00710-8&rft_dat=%3Cproquest_cross%3E2309501057%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2309501057&rft_id=info:pmid/31654156&rfr_iscdi=true |